Literature DB >> 21277694

Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.

Ross A Abrams1, Kathryn A Winter, William F Regine, Howard Safran, John P Hoffman, Robert Lustig, Andre A Konski, Al B Benson, John S Macdonald, Tyvin A Rich, Christopher G Willett.   

Abstract

PURPOSE: In Radiation Therapy Oncology Group 9704, as previously published, patients with resected pancreatic adenocarcinoma received continuous infusion 5-FU and concurrent radiotherapy (5FU-RT). 5FU-RT treatment was preceded and followed by randomly assigned chemotherapy, either 5-FU or gemcitabine. This analysis explored whether failure to adhere to specified RT guidelines influenced survival and/or toxicity. METHODS AND MATERIALS: RT requirements were protocol specified. Adherence was scored as per protocol (PP) or less than per protocol (<PP). Scoring occurred after therapy but before trial analysis and without knowledge of individual patient treatment outcomes. Scoring was done for all tumor locations and for the subset of pancreatic head location.
RESULTS: RT was scored for 416 patients: 216 PP and 200 <PP. For all pancreatic sites (head, body/tail) median survival (MS) for PP vs. <PP was 1.74 vs. 1.46 years (log-rank p = 0.0077). In multivariate analysis, PP vs. <PP score correlated more strongly with MS than assigned treatment arm (p = 0.014, p = NS, respectively); for patients with pancreatic head tumors, both PP score and gemcitabine treatment correlated with improved MS (p = 0.016, p = 0.043, respectively). For all tumor locations, PP score was associated with decreased risk of failure (p = 0.016) and, for gemcitabine patients, a trend toward reduced Grade 4/5 nonhematologic toxicity (p = 0.065).
CONCLUSIONS: This is the first Phase III, multicenter, adjuvant protocol for pancreatic adenocarcinoma to evaluate the impact of adherence to specified RT protocol guidelines on protocol outcomes. Failure to adhere to specified RT guidelines was associated with reduced survival and, for patients receiving gemcitabine, trend toward increased nonhematologic toxicity.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21277694      PMCID: PMC3133855          DOI: 10.1016/j.ijrobp.2010.11.039

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  37 in total

1.  A meta-analysis of thoracic radiotherapy for small-cell lung cancer.

Authors:  J P Pignon; R Arriagada; D C Ihde; D H Johnson; M C Perry; R L Souhami; O Brodin; R A Joss; M S Kies; B Lebeau
Journal:  N Engl J Med       Date:  1992-12-03       Impact factor: 91.245

2.  Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.

Authors:  C J Yeo; R A Abrams; L B Grochow; T A Sohn; S E Ord; R H Hruban; M L Zahurak; W C Dooley; J Coleman; P K Sauter; H A Pitt; K D Lillemoe; J L Cameron
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

3.  Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung.

Authors:  M C Perry; W L Eaton; K J Propert; J H Ware; B Zimmer; A P Chahinian; A Skarin; R W Carey; H Kreisman; C Faulkner
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

4.  Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.

Authors:  M Overgaard; M B Jensen; J Overgaard; P S Hansen; C Rose; M Andersson; C Kamby; M Kjaer; C C Gadeberg; B B Rasmussen; M Blichert-Toft; H T Mouridsen
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

5.  Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

Authors:  M Overgaard; P S Hansen; J Overgaard; C Rose; M Andersson; F Bach; M Kjaer; C C Gadeberg; H T Mouridsen; M B Jensen; K Zedeler
Journal:  N Engl J Med       Date:  1997-10-02       Impact factor: 91.245

6.  Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.

Authors:  M J O'Connell; J A Martenson; H S Wieand; J E Krook; J S Macdonald; D G Haller; R J Mayer; L L Gunderson; T A Rich
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

7.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.

Authors:  T P Miller; S Dahlberg; J R Cassady; D J Adelstein; C M Spier; T M Grogan; M LeBlanc; S Carlin; E Chase; R I Fisher
Journal:  N Engl J Med       Date:  1998-07-02       Impact factor: 91.245

8.  Prolongation of the disease-free interval in surgically treated rectal carcinoma.

Authors: 
Journal:  N Engl J Med       Date:  1985-06-06       Impact factor: 91.245

9.  Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1988-07-20       Impact factor: 13.506

10.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Authors:  John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

View more
  73 in total

Review 1.  Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma.

Authors:  Daneng Li; Eileen M O'Reilly
Journal:  Semin Oncol       Date:  2014-12-09       Impact factor: 4.929

2.  Trends in the use of pre-operative radiation for adenocarcinoma of the pancreas in the United States.

Authors:  Erin E Burke; Schelomo Marmor; Pamela R Portschy; Beth A Virnig; Lawrence C Cho; Todd M Tuttle; Eric H Jensen
Journal:  HPB (Oxford)       Date:  2015-02-28       Impact factor: 3.647

3.  The controversial role of chemoradiation for patients with locally advanced pancreatic cancer.

Authors:  Jason E Faris; Jennifer Y Wo
Journal:  Oncologist       Date:  2013-09-10

4.  Quantifying Unnecessary Normal Tissue Complication Risks due to Suboptimal Planning: A Secondary Study of RTOG 0126.

Authors:  Kevin L Moore; Rachel Schmidt; Vitali Moiseenko; Lindsey A Olsen; Jun Tan; Ying Xiao; James Galvin; Stephanie Pugh; Michael J Seider; Adam P Dicker; Walter Bosch; Jeff Michalski; Sasa Mutic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-03       Impact factor: 7.038

Review 5.  Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.

Authors:  Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad
Journal:  Ann Surg Oncol       Date:  2013-02-23       Impact factor: 5.344

Review 6.  Locally advanced gastroesophageal junction tumor: a treatment dilemma.

Authors:  Noman Ashraf; Sarah Hoffe; Richard Kim
Journal:  Oncologist       Date:  2015-01-05

Review 7.  Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials.

Authors:  Nitin Ohri; Xinglei Shen; Adam P Dicker; Laura A Doyle; Amy S Harrison; Timothy N Showalter
Journal:  J Natl Cancer Inst       Date:  2013-03-06       Impact factor: 13.506

Review 8.  Improving radiotherapy quality assurance in clinical trials: assessment of target volume delineation of the pre-accrual benchmark case.

Authors:  S Gwynne; E Spezi; D Sebag-Montefiore; S Mukherjee; E Miles; J Conibear; J Staffurth
Journal:  Br J Radiol       Date:  2013-02-07       Impact factor: 3.039

9.  Radiation therapy quality assurance in clinical trials--Global Harmonisation Group.

Authors:  Christos Melidis; Walter R Bosch; Joanna Izewska; Elena Fidarova; Eduardo Zubizarreta; Satoshi Ishikura; David Followill; James Galvin; Ying Xiao; Martin A Ebert; Tomas Kron; Catharine H Clark; Elizabeth A Miles; Edwin G A Aird; Damien C Weber; Kenneth Ulin; Dirk Verellen; Coen W Hurkmans
Journal:  Radiother Oncol       Date:  2014-05-08       Impact factor: 6.280

10.  Proton therapy may allow for comprehensive elective nodal coverage for patients receiving neoadjuvant radiotherapy for localized pancreatic head cancers.

Authors:  Richard Y Lee; Romaine C Nichols; Soon N Huh; Meng W Ho; Zuofeng Li; Robert Zaiden; Ziad T Awad; Bestoun Ahmed; Bradfors S Hoppe
Journal:  J Gastrointest Oncol       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.